Moncyte Health

At MONCYTE Health, we help doctors and pharmaceutical companies better understand and treat cardiovascular disease — starting at the cellular level. From a single blood sample, our technology detects early biological changes that drive inflammation and plaque progression. By integrating robotics, high-resolution imaging, AI, and advanced software, we deliver scalable, precise insights into cellular disease activity — going beyond traditional biomarker testing. Our clinical solution enables doctors to assess residual cardiovascular risk and receive optimal decision-making support. For pharmaceutical partners, MONCYTE Health provides novel readouts to evaluate drug effects on cellular drivers of disease, optimize patient recruitment, and generate data that can support market access. Founded in Finland in 2024, MONCYTE brings cutting-edge science and clinical insight to shape the future of cardiovascular diagnostics.